Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Primary Sclerosing Cholangitis (PSC) Industry 2021-2031 - Epidemiology, Pipeline Drugs, Key Upcoming Events, Probability of Success, Clinical Trial Landscape, and More -

December 22, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Dec 22, 2021--

The “Market Spotlight: Primary Sclerosing Cholangitis (PSC)” report has been added to’s offering.

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) industry, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.


Key Takeaways

  • The publisher estimates that in 2019, there were 241,800 prevalent cases of primary sclerosing cholangitis (PSC) worldwide among adults aged 30 years and over, and forecasts that number to increase to 277,300 prevalent cases by 2028.
  • The majority of industry-sponsored drugs in active clinical development for PSC are in Phase II, with just a single product in Phase III.
  • Therapies in the pipeline for PSC focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with one product being tested in an intravenous formulation.
  • The only high-impact upcoming event for drugs in the PSC space is topline Phase II trial results for HTD1801. The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 19.2%, and the average probability a drug advances from Phase III is 67.3%. Drugs, on average, take 10 years from Phase I to approval, compared to 9.4 years in the overall autoimmune/immunology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PSC have been in the early and midphases of development, with 85% of trials in Phase I-II, and only 15% in Phase III.
  • The US leads in terms of the number of PSC clinical trials globally, while the UK leads the major European markets.
  • Gilead Sciences has three completed trials and two ongoing trials in PSC.
  • Gilead Sciences and Takeda are the only companies to have conducted Phase III trials for PSC.

Key Topics Covered


Key Takeaways

Disease Background

  • Subtypes



Pipeline Drugs

Recent Events and Analyst Opinion

  • Seladelpar for PSC (November 25, 2019)

Key Upcoming Events

Probability of Success

Clinical Trial Landscape

  • Sponsors by status
  • Sponsors by phase




For more information about this report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 12/22/2021 11:47 AM/DISC: 12/22/2021 11:47 AM